Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NASDAQ:ECOR NASDAQ:ICCM NASDAQ:LNSR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.47+7.2%$4.68$1.03▼$32.10$77.79M3.472.15 million shs462,690 shsECORelectroCore$10.21+4.6%$6.60$4.16▼$10.27$84.70M0.8380,523 shs77,447 shsICCMIceCure Medical$0.20-10.0%$0.32$0.20▼$1.40$16.00M0.4495,280 shs1.91 million shsLNSRLENSAR$5.70-1.7%$5.73$5.06▼$13.67$68.97M0.8787,750 shs29,527 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+30.52%+17.94%+291.57%+696,999,900.00%ECORelectroCore0.00%+46.33%+49.92%+25.61%+92.13%ICCMIceCure Medical0.00%-6.81%-23.43%-65.57%-79.14%LNSRLENSAR0.00%-4.76%+10.90%-51.63%-57.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.47+7.2%$4.68$1.03▼$32.10$77.79M3.472.15 million shs462,690 shsECORelectroCore$10.21+4.6%$6.60$4.16▼$10.27$84.70M0.8380,523 shs77,447 shsICCMIceCure Medical$0.20-10.0%$0.32$0.20▼$1.40$16.00M0.4495,280 shs1.91 million shsLNSRLENSAR$5.70-1.7%$5.73$5.06▼$13.67$68.97M0.8787,750 shs29,527 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+30.52%+17.94%+291.57%+696,999,900.00%ECORelectroCore0.00%+46.33%+49.92%+25.61%+92.13%ICCMIceCure Medical0.00%-6.81%-23.43%-65.57%-79.14%LNSRLENSAR0.00%-4.76%+10.90%-51.63%-57.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/AECORelectroCore 2.00Hold$18.0076.38% UpsideICCMIceCure Medical 2.40Hold$2.09960.91% UpsideLNSRLENSAR 2.33Hold$10.0075.44% UpsideCurrent Analyst Ratings BreakdownLatest ICCM, ECOR, LNSR, and AGPU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026ICCMIceCure Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $1.005/11/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/1/2026LNSRLENSAR Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$10.003/27/2026ECORelectroCore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ECORelectroCore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/17/2026LNSRLENSAR BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$120K647.40N/AN/A$11.69 per share0.64ECORelectroCore$32.03M2.64N/AN/A($0.21) per share-48.60ICCMIceCure Medical$3.38M4.73N/AN/A$0.12 per share1.64LNSRLENSAR$58.44M1.18N/AN/A($2.18) per share-2.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$8.18N/AN/AN/A-470,383.31%-7,363.67%-626.32%N/AECORelectroCore-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%8/5/2026 (Estimated)ICCMIceCure Medical-$15.06M-$0.24N/AN/AN/A-441.60%-211.73%-119.13%8/12/2026 (Estimated)LNSRLENSAR-$34.28M-$0.58N/AN/AN/A50.94%-183.19%42.26%8/6/2026 (Estimated)Latest ICCM, ECOR, LNSR, and AGPU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AGPUPredictive OncologyN/A-$0.36N/A-$0.36N/A$0.04 million5/12/2026Q1 2026ICCMIceCure Medical-$0.03-$0.06-$0.03$0.06$1.34 million$0.91 million5/8/2026Q1 2026LNSRLENSAR$0.1850$1.56+$1.3750N/A$13.40 million$13.43 million5/6/2026Q1 2026ECORelectroCore-$0.59-$0.59N/A-$0.59$9.01 million$9.58 million3/31/2026Q4 2025AGPUPredictive OncologyN/A$122.75N/A$122.75N/A$0.01 million3/31/2026Q4 2025LNSRLENSAR-$0.10-$0.12-$0.02-$0.12$20.30 million$16.03 million3/19/2026Q4 2025ECORelectroCore-$0.35-$0.34+$0.01-$0.34$9.09 million$9.24 million3/17/2026Q4 2025ICCMIceCure Medical-$0.04-$0.06-$0.02-$0.0620$1.30 million$1.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A8.898.89ECORelectroCoreN/A1.020.86ICCMIceCure MedicalN/A2.521.97LNSRLENSARN/A2.381.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%ECORelectroCore26.74%ICCMIceCure Medical0.62%LNSRLENSAR40.15%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%ECORelectroCore13.80%ICCMIceCure Medical2.44%LNSRLENSAR66.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology3010.40 million10.28 millionN/AECORelectroCore508.30 million7.15 millionNot OptionableICCMIceCure Medical6081.24 million79.26 millionNot OptionableLNSRLENSAR11012.10 million4.12 millionOptionableICCM, ECOR, LNSR, and AGPU HeadlinesRecent News About These CompaniesLENSAR (NASDAQ:LNSR) Announces Quarterly Earnings ResultsMay 9, 2026 | marketbeat.comLENSAR signals 2027 as “really, really good” year as it rebuilds distributor orders after Alcon deal terminationMay 9, 2026 | seekingalpha.comLENSAR Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comLENSAR, Inc. (LNSR) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comLENSAR® Reports First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comLENSAR® to Report First Quarter 2026 Results on May 8, 2026April 30, 2026 | globenewswire.comLensar Earnings Call: Recurring Revenue Shines Amid DisruptionApril 22, 2026 | theglobeandmail.comHow The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside PotentialApril 21, 2026 | finance.yahoo.comCedar Grove Capital Management’s Views on LENSAR (LNSR)April 20, 2026 | insidermonkey.comLENSAR Announces Upcoming Chief Financial Officer TransitionApril 15, 2026 | tipranks.comLENSAR (LNSR) price target decreased by 32.00% to 8.67April 10, 2026 | msn.comHow The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target ResetApril 5, 2026 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Q4 2025 Earnings Call TranscriptApril 4, 2026 | insidermonkey.comLENSAR Inc (LNSR) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst ChallengesApril 3, 2026 | finance.yahoo.comEarnings To Watch: LENSAR Inc (LNSR) Reports Q4 2025 ResultMarch 31, 2026 | finance.yahoo.comLENSAR, Inc. (LNSR) Q4 2025 Earnings Call TranscriptMarch 31, 2026 | seekingalpha.comLENSAR, Inc.: LENSAR Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdateMarch 31, 2026 | finanznachrichten.deLENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comBTIG upgrades LENSAR (LNSR)March 19, 2026 | msn.comBiggest stock movers Tuesday: DAL, LLY, BYND, LNSR, and moreMarch 17, 2026 | seekingalpha.comLENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory ReviewMarch 17, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 2026Berkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record HighsBy Thomas Hughes | May 15, 2026Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemBy Dan Schmidt | May 30, 2026ICCM, ECOR, LNSR, and AGPU Company DescriptionsPredictive Oncology NASDAQ:AGPU$7.47 +0.50 (+7.17%) As of 03:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.electroCore NASDAQ:ECOR$10.20 +0.45 (+4.56%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.IceCure Medical NASDAQ:ICCM$0.20 -0.02 (-10.05%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.LENSAR NASDAQ:LNSR$5.70 -0.10 (-1.72%) As of 03:07 PM Eastern This is a fair market value price provided by Massive. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
